STAT+: Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials
An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares down
An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre-market trading.
The drug, called itepekimab, carries high hopes as the companies look for the next medicine that can produce the successes seen with Dupixent, their jointly marketed blockbuster. Dupixent is approved for a number of immune-mediated diseases, and picked up the green light for COPD last year.
Sanofi shares slid some 5% Friday morning. In pre-market U.S. trading, Regeneron shares were down more than 10%.
